3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
35
Carcinoma, Non-Small-Cell Lung
32
Colorectal Neoplasms
19
Esophageal Squamous Cell Carcinoma
18
Stomach Neoplasms
17
Squamous Cell Carcinoma of Head and Neck
16
Rectal Neoplasms
11
Cholangiocarcinoma
11
Head and Neck Neoplasms
10
Small Cell Lung Carcinoma
9
Lung Neoplasms
9
Esophageal Neoplasms
9
Triple Negative Breast Neoplasms
8
Uterine Cervical Neoplasms
7
Nasopharyngeal Carcinoma
7
Urinary Bladder Neoplasms
6
Recurrence
6
Pancreatic Neoplasms
6
Neoplasms
6
Colonic Neoplasms
6
Melanoma
5
Hodgkin Disease
5
Biliary Tract Neoplasms
4
Adenocarcinoma of Lung
4
Sarcoma
3
Non-Muscle Invasive Bladder Neoplasms
3
Neoplasm Metastasis
3
NSCLC
3
Locally Advanced Rectal Cancer
3
Liver Neoplasms
3
Interventions
Cisplatin
28
Pemetrexed
24
pembrolizumab
12
Nivolumab
10
Carboplatin
9
atezolizumab
7
Gemcitabine
7
Cyclophosphamide
7
durvalumab
6
Drug Therapy
6
sodium thiosulfate
5
Radiotherapy, Intensity-Modulated
5
tremelimumab
4
aldesleukin
4
Radiotherapy
4
Interleukin-2
4
sargramostim
3
Vinorelbine
3
Platinum
3
Photochemotherapy
3
Ipilimumab
3
Doxorubicin
3
Dihematoporphyrin Ether
3
Chemotherapy, Adjuvant
3
Cerebral Decortication
3
vatalanib
2
regorafenib
2
niraparib
2
lenvatinib
2
cemiplimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Mesothelioma, Malignant
×
tislelizumab
×
Clear all
NCT05582031
2023-06-07
REFIT-MSS
Translational Research in Oncology
Phase 2
Withdrawn